Biotech Industry Examiner’s Post

Could a game-changing solution to the treatment of solid tumors and autoimmune diseases be on the horizon? A fascinating new article from UKT news dives into the remarkable possibilities of T-Cypher Bio's D-Cypher, an integrated platform that could potentially revolutionize the biotech industry. This Oxford-based startup are planning to overcome the challenges met with current therapeutics, as they push the boundaries of science to transform lives. Don't miss out on this enlightening read: https://UKT.news/?p=10417 #Biotech #HealthcareInnovation #TCRBiotherapeutics #DCypher #OxfordStartup

After decades of research, there remains a dearth of impactful treatments for complex, neurological diseases like Alzheimer’s, Parkinson’s and Rett syndrome. Lucy Therapeutics, who today announced $12.5 million in additional funding co-led by Engine Ventures and Safar Partners, with new participation from Bill Gates, Parkinson's UK, and The Michael J. Fox Foundation for Parkinson's Research, believes we must move away from the siloed, genetic-only approach to studying neurological disease to truly break through. LucyTx seeks to understand the mitochondrial roots of complex diseases, ultimately identifying new drug targets by analyzing a wide range of disease drivers including environmental and genetic factors. With three drug discovery programs already in its pipeline, we look forward to seeing what’s next for the company. https://lnkd.in/eq8m_DFA

𝐅𝐥𝐚𝐠𝐬𝐡𝐢𝐩 𝐏𝐢𝐨𝐧𝐞𝐞𝐫𝐢𝐧𝐠 𝐋𝐚𝐮𝐧𝐜𝐡𝐞𝐬 𝐏𝐫𝐨𝐥𝐨𝐠𝐮𝐞 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞𝐬: 𝐋𝐞𝐯𝐞𝐫𝐚𝐠𝐢𝐧𝐠 𝐕𝐢𝐫𝐚𝐥 𝐏𝐫𝐨𝐭𝐞𝐢𝐧𝐬 𝐟𝐨𝐫 𝐃𝐫𝐮𝐠 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 Flagship Pioneering Flagship Pioneering's latest venture, Prologue Medicines Prologue Medicines, has launched with a $50 million investment to propel its innovative DELVE platform. DELVE, a cutting-edge proteome-assisted drug discovery technology, capitalizes on the expansive viral proteome to identify potential therapeutic molecules. Under the leadership of CEO Lovisa Afzelius Lovisa Afzelius, Prologue is dedicated to developing a robust pipeline of drug candidates, with a primary focus on cancer, metabolic, and immunology indications. Afzelius, alongside co-founders Theonie Anastassiadis and Hozefa Bandukwala, envisions Prologue as a frontrunner in leveraging viral proteins for medical advancements. With Noubar Afeyan as chairman, Prologue stands as a significant addition to Flagship's portfolio, which also includes Empress Therapeutics and ProFound Therapeutics. This strategic move reinforces Flagship's commitment to pioneering breakthroughs in the life sciences sector. #PrologueMedicines #DrugDiscovery #ViralProteins #FlagshipPioneering #DELVEPlatform #TherapeuticMolecules #HealthcareInnovation #InvestmentInScience

Novo Holdings led a $100 million Series C Financing in Asceneuron, a clinical stage biotech company developing small molecules targeting tau protein aggregation, a driver of neurodegenerative disease. The financing will be used to advance Asceneuron’s lead asset ASN51 into Phase 2 clinical development for the treatment of Alzheimer’s disease.   Alzheimer’s disease is an area of very high unmet medical need with a lack of oral disease modifying therapies. Learn more about Asceneuron and the science behind this therapy below. #ventureinvestments #alzheimers

We look forward to supporting Asceneuron SA’s seasoned management team as they advance ASN 51, a highly promising oral OGA inhibitor into Phase2 testing for Alzheimer’s disease. This sizeable and oversubscribed financing alongside top-tier investors, led by Novo Holdings, is a testament to the high quality of the opportunity. It throws a spotlight on an exciting novel oral compound class of OGA inhibitors targeting a key disease driver protein: Tau, particularly intracellularly, where the vast majority of Tau associated pathology resides in Alzheimer’s disease. The potential for success in Phase 2 of this novel class of oral agents offers the promise to help significantly advance the Alzheimer’s field, currently dominated by anti-amyloid injectable drugs. With this latest biotech deal in Switzerland, the Novo Holdings Venture Investments team is continuing its mission to identify and invest in the most innovative and exciting European and US biotech companies which can help to truly advance patient care. Magne Stoknes Principal, joins me on the Board of Asceneuron as Board Observer. #NovoHoldings #Alzheimer’s #Swissbiotech #CNS #Neurodegeneration #Europeanlifesiences #venturecapital

Phialogics is a preclinical biotech company specialized in engineering next-generation biologics to rebalance the immune response in acute and chronic inflammation. Phialogics concept is based on the targeted modification of immunoglobulin receptor domains (IgVs) to modulate immune response in inflammatory diseases. IgV mediated receptor-ligand interaction represents a significant source of novel biologics. Phialogics lead molecules replicate endogenous protein-protein interactions to efficiently modulate the function of their target receptor. So far, only this unique platform technology can achieve such a high level of precision. Meet Phialogics AG @ #Sachs_ELSF More Info @ https://lnkd.in/dQWhKYkV #ELSF2024 #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #RisingStars #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #SachsSpringLifeSciencesWeek #SSLSW

📣 Calling Supply Chain, Logistics and Clinical Operations Leaders!   🌐 We are excited to announce the only meeting uniting experts from logistics and clinical operations teams to collaboratively solve the challenges facing the supply chains critical to Cell Therapy.   ⬇ Check out the post below to get caught up on all the information regarding the 5th Supply Chain and Logistics for Cell Therapies Summit, as the community aims to streamline supply chains to get therapies to patients faster! #supplychain #celltherapy #clinicaloperations #cellandgene #logistics

Sangamo and Genentech Forge $50M Partnership to Tackle Alzheimer’s Sangamo Therapeutics, Inc. has secured a significant lifeline through a $50M upfront deal with Roche's Genentech, focusing on innovative genomic medicines for neurodegenerative diseases. This global licensing agreement grants Genentech exclusive rights to Sangamo’s proprietary zinc finger repressors, targeting the tau gene associated with Alzheimer’s disease and another undisclosed neurology target. What could that other “undisclosed” neurology target be? Key Highlights: Exclusive Rights: Genentech now holds exclusive rights to Sangamo’s STAC-BBB technology, which has shown exceptional blood-brain barrier penetration and brain transduction in animal models.  Collaborative Effort: Sangamo will handle technology transfer and preclinical activities, while Genentech will spearhead clinical development, regulatory efforts, manufacturing, and global commercialization.  Financial Boost: The deal includes $50M upfront and potential milestone payments up to $1.9 billion, plus tiered royalties. This partnership highlights the critical role of innovative collaborations in advancing treatments for neurodegenerative diseases. Do you think this deal might have been clinched during the AAIC conference in Philadelphia last week? Tell us what you think. “Through groundbreaking research and partnerships with companies such as Sangamo, we are committed to pursuing important breakthroughs in both early diagnosis and treatment.” Boris L. Zaïtra, head of Roche’s corporate business development arm, said in an Aug. 6 release. Read more in the article in the comment section. #Biotechnology #GeneTherapy #NeurodegenerativeDiseases #SangamoTherapeutics #Roche #Genentech #Innovation #Healthcare #LifeSciences

Great to be at #bioequity24 supporting and representing MitoRx Therapeutics as we seek investors for our Series A raise. MitoRx Therapeutics is an Oxford based preclinical stage platform biotech developing mitochondrial-targeted small molecules that uniquely restore sulfide-signaling, a conserved system required for adaptive metabolism, recently achieving preclinical platform validation. We have generated positive results in 3 preclinical programs in neuromuscular, obesity and lung inflammatory disease. In a severe fibrotic rodent model of Duchenne MD muscle degeneration is halted and impaired weight gain is reversed, a unique metabolic rescue among muscular dystrophy efforts. In a rodent obesity model, we observed highly significant reduction in weight gain, inflammation and liver injury. In a COPD model with our compounds reduce fibrosis, blunt inflammasome activation and preserve function. MitoRx Therapeutics have raised £5m since 2022, built a team that has taken 5 drugs to market, and filed on five compositions of matter patents. Our approach in highly innovative: first in class, first in mechanism and first in target. We are seeking research collaboration and option deals with pharma and investors who want to back us to the clinic.

[Portfolio news] Insightful article from Labiotech.eu featuring 19 promising French biotech companies, with two shining stars from our portfolio! 🌐💼 🌟 DiogenX focuses on regenerating insulin-producing beta cells to transform diabetes treatment while SparingVision develops a pipeline of gene therapies for inherited retinal diseases. Their recent milestones, from funding successes to clinical advancements, underscore the strength of our investment strategy. Quietly leading in the biotech landscape, our portfolio companies reflect the remarkable potential found in #France. Our #early investment strategy in France, dating back to 2017, has positioned us at the forefront of biotech innovation. DiogenX and SparingVision exemplify the prowess of the French biotech landscape, where groundbreaking ideas flourish into globally recognized ventures. 🚀 Investing early, fostering excellence – that's our commitment to shaping the future of healthcare. #Biotech #VentureBuilder #French #Innovation #DiogenX #SparingVision Benjamin CHARLES Stephane Boissel Alain Huriez Geoffroy De Ribains